science pharmaceutical expo biotech jobs
Originally published online as doi:10.1189/jlb.1204715 on April 7, 2005

Published online before print April 7, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.1204715v1
78/1/195    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, M. P.
Right arrow Articles by Wahl, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, M. P.
Right arrow Articles by Wahl, L. M.
(Journal of Leukocyte Biology. 2005;78:195-201.)
© 2005 by Society for Leukocyte Biology

Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture

Min P. Kim*,{dagger}, Min Zhou* and Larry M. Wahl*,1

* Immunopathology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, and
{dagger} Howard Hughes Medical Institute–National Institutes of Health Research Scholar, Bethesda, Maryland

1 Correspondence: Immunopathology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, 30 Convent Drive, Building 30, Room 325, Bethesda, MD 20892-4352. E-mail: lwahl{at}dir.nidcr.nih.gov

Angiotensin II (Ang II)-mediated hypertension increases the risk for acute coronary syndrome, a consequence of atherosclerotic plaque rupture, which may be caused by matrix metalloproteinases (MMPs). Here, we show that human primary monocytes stimulated with tumor necrosis factor {alpha} (TNF-{alpha}) and granulocyte macrophage-colony stimulating factor (GM-CSF) release Ang II, which is an integral component of the signal transduction pathway that leads to MMP-1 production. An Ang II-mediated increase in MMP-1 synthesis occurred only in conjunction with cytokine stimulation. Moreover, Ang II mediated its effect through the Ang II type 2 (AT2) receptor, as demonstrated by enhancement of MMP-1 production by an AT2 agonist, CGP-42112A, and inhibition of MMP-1 production by PD1233319, an AT2 antagonist. Additionally, exogenous Ang II caused a significant enhancement in MMP-1 production by cytokine-stimulated monocytes, and the most effective enhancement occurrred when Ang II was added 6 h after stimulation. Furthermore, Ang II and the AT2 agonist increased prostaglandin E2 (PGE2), which in turn mediated the increase in MMP-1, as shown by the inhibition of MMP-1 by indomethacin or aspirin. In contrast, the AT2 antagonist inhibited the PGE2 production induced by TNF-{alpha} and GM-CSF. Ang II, through its interaction with the AT2 receptor, has a central role in mediating the PGE2-dependent production of MMP-1 by monocytes stimulated with TNF-{alpha} and GM-CSF. These observations provide insight into the association between hypertension and acute coronary syndrome and a possible mechanism by which Ang-converting enzyme inhibitor and aspirin may reduce the risk for heart attacks.

Key Words: angiotensin II receptor subtype 2 • inflammation • cytokines




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
H. Jarvelainen, A. Sainio, M. Koulu, T. N. Wight, and R. Penttinen
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy
Pharmacol. Rev., June 1, 2009; 61(2): 198 - 223.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
E. Sanchez-Lemus, J. Benicky, J. Pavel, I. M. Larrayoz, J. Zhou, M. Baliova, T. Nishioku, and J. M. Saavedra
Angiotensin II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2009; 296(5): R1376 - R1384.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
M. H Barreta, J. F. C Oliveira, R. Ferreira, A. Q Antoniazzi, B. G Gasperin, L. R Sandri, and P. B. D Goncalves
Evidence that the effect of angiotensin II on bovine oocyte nuclear maturation is mediated by prostaglandins E2 and F2{alpha}
Reproduction, December 1, 2008; 136(6): 733 - 740.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
R. Ferreira, J. F. Oliveira, R. Fernandes, J. F. Moraes, and P. B. Goncalves
The role of angiotensin II in the early stages of bovine ovulation
Reproduction, November 1, 2007; 134(5): 713 - 719.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Yusof, K. Kamada, F. Spencer Gaskin, and R. J. Korthuis
Angiotensin II mediates postischemic leukocyte-endothelial interactions: role of calcitonin gene-related peptide
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3032 - H3037.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. Cuenca, P. Martin-Sanz, A. M. Alvarez-Barrientos, L. Bosca, and N. Goren
Infiltration of Inflammatory Cells Plays an Important Role in Matrix Metalloproteinase Expression and Activation in the Heart during Sepsis
Am. J. Pathol., November 1, 2006; 169(5): 1567 - 1576.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. H. Strauss and A. S. Hall
Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox
Circulation, August 22, 2006; 114(8): 838 - 854.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Bolbrinker, S. Markovic, M. Wehland, W. B. W. H. Melenhorst, H. van Goor, and R. Kreutz
Expression and Response to Angiotensin-Converting Enzyme Inhibition of Matrix Metalloproteinases 2 and 9 in Renal Glomerular Damage in Young Transgenic Rats with Renin-Dependent Hypertension
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 8 - 16.
[Abstract] [Full Text] [PDF]